ERITROPOIETINA BULA PDF

A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl ; A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney Int ; Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer.

Author:Tegor Zuluzuru
Country:Georgia
Language:English (Spanish)
Genre:Art
Published (Last):6 September 2017
Pages:439
PDF File Size:10.81 Mb
ePub File Size:6.59 Mb
ISBN:424-9-27226-872-4
Downloads:50249
Price:Free* [*Free Regsitration Required]
Uploader:Mezikinos



O ferro dextran pode ser administrado por via endovenosa ou intramuscular. Os pacientes foram reavaliados clinicamente e laboratorialmente nas semanas 1, 4, 8, 12, 16 e Os pacientes foram reavaliados clinicamente e laboratorialmente nas semanas 4, 12, 24 e Agentes estimuladores da eritropoiese eritropoetina, darbepoetina.

Barretto e cols. Potencial Conflito de Interesses. Fontes de Financiamento. Arq Bras Cardiol. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. Heart failure: clinical implications of systolic and diastolic dysfunction. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.

Am J Cardiol. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure.

Anemia and mortality in heart failure patients: a systematic review and meta-analysis. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure-the anemia in chronic heart failure: Outcomes and Resource Utilization ANCHOR study.

Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients. BMC Nephrol. Silverberg DS. The role of erythropoiesis stimulating agents and intravenous IV iron in the cardio renal anemia syndrome. Heart Fail Rev. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. Sociedade Brasileira de Cardiologia. Ferric carboxymaltose in patients with heart failure and iron deficiency. New Engl J Med. Anemia in chronic heart failure: can we treat?

What to treat? Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. Anand IS. Anemia chronic heart failure: implications and treatment options. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 patients with new-onset heart failure.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. The role of anaemia in patients with congestive heart failure: a short review. Eur J Heart Fail. The anemia of heart failure. Acta Haematol. Mediators of anemia in chronic heart failure.

Heart Fail Clin. Six truisms concerning ACE and the renin-angiotensin system educed from the genetic analysis of mice. Circ Res. Nutritional anaemias. Rationale and design of Ferinject assessment in patients with iron deficiency and chronic heart failure FAIRHF study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anemia.

A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis dependent CKD. Kidney Int. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant. Iron therapy in chronic kidney disease: current controversies. J Ren Care. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

Beris P, Maniatis A. Role of intravenous iron therapy in anemia management: state of the art. Semin Hematol. Iron deficiency anemia treatment with parenteral iron. Rev Bras Hematol Hemoter. Iron deficiency anemia in the adult - causes, diagnosis and treatment. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.

Goldsmith D. Clin J Am Soc Nephrol. Singh AK. J Am Soc Nephrol. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer associated anemia.

Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.

Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev. Impact of erythropoiesis-stimulating agents on energy and physical function in non-dialysis CKD patients with anemia: a systematic review. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis stimulating agents. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review.

Congest Heart Fail. Routine assessment of iron status in all patients with heart failure may identify those at risk of developing anemia. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Jelani Q, Katz SD. Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease. Cardiol Rev. All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License.

Services on Demand Journal. How to cite this article.

BTA40 700B PDF

Resultados de eficácia deca durabolin

.

CISSUS QUADRANGULARIS TO BONE PDF

.

D38999 GLENAIR PDF

.

Related Articles